High-Dose Therapy and Autologous Hematopoietic Progenitor Cells Transplantation for Recurrent or Refractory Hodgkin's Lymphoma : Analysis of King Hussein Cancer Center Results and Prognostic Variables

Abstract EN

Purpose.

to evaluate the outcome of patients with Hodgkin’s lymphoma who underwent autologous transplantation at KHCC bone marrow transplant program.

Patients and Methods.

Over 6 years, 63 patients with relapsed or refractory Hodgkin’s lymphoma underwent high dose chemotherapy followed by autologous transplant.

There were 25.4% patients in complete remission (CR), 71.4% with chemotherapy responsive disease at the time of transplant.

Prior to conditioning regimen, 56% received two chemotherapy lines, and, 44% received more than two lines.

Results.

The main outcomes of the study are the rate of complete remission at day 100, overall survival (OS), relapse-free survival (RFS), The impact of the following variables on OS and RFS: (a) disease status at the time of transplant, (b) number of chemotherapy lines prior to conditioning, (c) age group, (d) time of relapse < or >12 months were investigated.

The CR at day 100 was 57%.

The median overall survival for the whole group was 40.6 months; the median RFS was 20 months.

The only factor which significantly impacts the study outcomes was the number of chemotherapy lines prior to conditioning on OS in favor of patients received two lines.

Conclusion.

In our study only the number of chemotherapy lines received before conditioning had statistically significant impact on OS.